{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T02:24:11Z","timestamp":1785637451440,"version":"3.56.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100022083","name":"VLIRUOS","doi-asserted-by":"publisher","award":["Global Minds"],"award-info":[{"award-number":["Global Minds"]}],"id":[{"id":"10.13039\/501100022083","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022083","name":"VLIRUOS","doi-asserted-by":"publisher","award":["TZ2022TEA530A101"],"award-info":[{"award-number":["TZ2022TEA530A101"]}],"id":[{"id":"10.13039\/501100022083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To curb HIV infection rate in Tanzania, antiretroviral therapy (ART) has been scaled up since 2006, and in 2019, the country shifted to regimen including dolutegravir as a default first line. We assessed the success of ART and the contribution of HIV drug resistance (HIVDR) to unsuppressed viral loads. Between February and May 2023 a cross-sectional survey with random sampling was conducted in the six clinics in an urban cohort in Dar es Salaam. Patients with unsuppresed viral loads (local criteria viral load (VL)\u2009\u2265\u20091000 copies\/mL) were tested for HIVDR mutations using the WHO adapted protocol for plasma samples. Mutations were interpreted using the Stanford HIVDR database. In total 600 individuals participated in this survey, the majority were female (76.83%), mean age (<jats:inline-formula><jats:alternatives><jats:tex-math>$$\\pm$$<\/jats:tex-math><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\">\n                  <mml:mo>\u00b1<\/mml:mo>\n                <\/mml:math><\/jats:alternatives><\/jats:inline-formula> standard deviation) was 44.0 (<jats:inline-formula><jats:alternatives><jats:tex-math>$$\\pm$$<\/jats:tex-math><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\">\n                  <mml:mo>\u00b1<\/mml:mo>\n                <\/mml:math><\/jats:alternatives><\/jats:inline-formula> 11.6) years. The median duration on ART (interquartile range) was 6.5 (3.9\u201310.2) years. Approximately 99% were receiving tenofovir\u2009+\u2009lamivudine\u2009+\u2009dolutegravir as a fixed dose combination. VL testing was successful in 99.67% (598\/600) of survey patients and only 33 had VL\u2009\u2265\u20091000 copies\/mL, resulting in a viral suppression level of 94.48% (565\/598, 95% CI 92.34\u201396.17%). For 23 samples, protease and reverse transcriptase (RT) genotyping were successful, with 13 sequences containing RT inhibitor surveillance drug resistance mutations (SDRMs) (56.5%). No SDRM against protease inhibitors were detected. Thirty samples were successfully genotyped for integrase with 3 sequences (10.08%) containing integrase strand transfer inhibitor (INSTI) SDRMs. In samples successfully genotyped in the three genetic regions, 68.18% (16\/22) had a genotypic susceptibility score (GSS)\u2009\u2265\u20092.5 for the concurrent regimen, implying factors beyond drug resistance caused the unsuppressed viral load. For five patients, GSS indicated that HIVDR may have caused the unsuppressed viral load. All three patients with INSTI resistance mutations were highly resistant to dolutegravir and accumulated nucleoside and non-nucleoside RT inhibitor HIVDR mutations. Although in this cohort the last 95 UNAIDS target was almost achieved, HIVDR mutations, including INSTIs resistance mutations were detected in HIV-positive individuals taking ART for at least one year. We recommend the design and implementation of high-impact interventions to prevent the increase of HIVDR, failure of dolutegravir and address the non-resistance factors in the study area.<\/jats:p>","DOI":"10.1038\/s41598-023-47795-1","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T15:02:36Z","timestamp":1700665356000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["High viral suppression and detection of dolutegravir-resistance associated mutations in treatment-experienced Tanzanian adults living with HIV-1 in Dar es Salaam"],"prefix":"10.1038","volume":"13","author":[{"given":"George M.","family":"Bwire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice Godwin","family":"Aiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idda H.","family":"Mosha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary S.","family":"Kilapilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alli","family":"Mangara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Kazonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janeth P.","family":"Swai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omary","family":"Swalehe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen","family":"Vercauteren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Temba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amani","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilhellmuss","family":"Mauka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Decouttere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Vandaele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael Z.","family":"Sangeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Japhet","family":"Killewo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Mieke","family":"Vandamme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"key":"47795_CR1","unstructured":"UNAIDS. Fact sheet - Latest global and regional statistics on the status of the AIDS epidemic. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/UNAIDS_FactSheet_en.pdf (2022)."},{"key":"47795_CR2","unstructured":"The United Republic of Tanzania. National Guidelines for Management of HIV and AIDS (Issue April). https:\/\/differentiatedservicedelivery.org\/wp-content\/uploads\/national_guidelines_for_the_management_of_hiv_and_aids_2019.pdf (2019)."},{"key":"47795_CR3","unstructured":"UNAIDS. (2014). Understanding Fast-Track: Accelerating Action to End the AIDS Epidemic by 2030. https:\/\/www.unaids.org\/en\/resources\/documents\/2014\/JC2686_WAD2014report."},{"key":"47795_CR4","unstructured":"HIV and AIDS Estimates Country factsheets United Republic of Tanzania 2021. (n.d.). Retrieved January 11, 2023, from file:\/\/\/Users\/georgebwire\/Downloads\/Country-factsheets-United-Republic-of-Tanzania-2021Change.pdf"},{"issue":"8","key":"47795_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-3156.2011.02877.x","volume":"17","author":"R Isingo","year":"2012","unstructured":"Isingo, R. et al. Trends in the uptake of voluntary counselling and testing for HIV in rural Tanzania in the context of the scale up of antiretroviral therapy. Trop. Med. Int. Health 17(8), 1. https:\/\/doi.org\/10.1111\/j.1365-3156.2011.02877.x (2012).","journal-title":"Trop. Med. Int. Health"},{"issue":"4","key":"47795_CR6","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3390\/microbiolres12040062","volume":"12","author":"RZ Sangeda","year":"2021","unstructured":"Sangeda, R. Z. et al. Development of HIV Drug Resistance in a Cohort of Adults on First-Line Antiretroviral Therapy in Tanzania during the Stavudine Era. Microbiol. Res. 12(4), 847\u2013861. https:\/\/doi.org\/10.3390\/microbiolres12040062 (2021).","journal-title":"Microbiol. Res."},{"key":"47795_CR7","unstructured":"National AIDS Control Programme. The United Republic of Tanzania. (2019). HIV Treatment Guideline. https:\/\/differentiatedservicedelivery.org\/wp-content\/uploads\/national_guidelines_for_the_management_of_hiv_and_aids_2019.pdf."},{"key":"47795_CR8","unstructured":"World Health Organization. (n.d.). HIV Drug Resistance Report 2021. In WHO Press (Issue July 2017). Retrieved February 28, 2023, from https:\/\/www.who.int\/publications\/i\/item\/9789240038608."},{"key":"47795_CR9","unstructured":"Optimization, O., & The, E. Dolutegravir (DTG) and the fixed dose combination (FDC) of tenofovir\/lamivudine\/dolutegravir (TLD). 2, 1\u201310 (2018)."},{"key":"47795_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232419","author":"VM Nabitaka","year":"2020","unstructured":"Nabitaka, V. M. et al. High acceptability and viral suppression of patients on Dolutegravir-based first-line regimens in pilot sites in Uganda: A mixedmethods prospective cohort study. PLoS ONE https:\/\/doi.org\/10.1371\/journal.pone.0232419 (2020).","journal-title":"PLoS ONE"},{"key":"47795_CR11","doi-asserted-by":"publisher","unstructured":"Mutagonda, R. F., Mlyuka, H. J., Maganda, B. A., & Kamuhabwa, A. A. R. Adherence, effectiveness and safety of dolutegravir based antiretroviral regimens among hiv infected children and adolescents in Tanzania. J. Int. Assoc. Prov. AIDS Care 21. https:\/\/doi.org\/10.1177\/23259582221109613 (2022).","DOI":"10.1177\/23259582221109613"},{"key":"47795_CR12","doi-asserted-by":"publisher","unstructured":"Kilapilo, M. S., Sangeda, R. Z., Bwire, G. M., Sambayi, G. L., Mosha, I. H., & Killewo, J. Adherence to Antiretroviral Therapy and Associated Factors Among People Living With HIV Following the Introduction of Dolutegravir Based Regimens in Dar es Salaam, Tanzania. J. Int. Assoc. Prov. AIDS Care 21. https:\/\/doi.org\/10.1177\/23259582221084543 (2022).","DOI":"10.1177\/23259582221084543"},{"issue":"11","key":"47795_CR13","doi-asserted-by":"publisher","first-page":"e664","DOI":"10.1016\/S2352-3018(21)00268-X","volume":"8","author":"V Kouamou","year":"2021","unstructured":"Kouamou, V., Inzaule, S. & Manasa, J. Dolutegravir drug-resistance monitoring in Africa. Lancet HIV 8(11), e664\u2013e666. https:\/\/doi.org\/10.1016\/S2352-3018(21)00268-X (2021).","journal-title":"Lancet HIV"},{"issue":"11","key":"47795_CR14","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1093\/jac\/dkac295","volume":"77","author":"S Henerico","year":"2022","unstructured":"Henerico, S. et al. Primary resistance against integrase strand transfer inhibitors in integrase strand transfer inhibitor-naive patients failing first- and second-line ART in Tanzania. J. Antimicrob. Chemother. 77(11), 3138\u20133143. https:\/\/doi.org\/10.1093\/jac\/dkac295 (2022).","journal-title":"J. Antimicrob. Chemother."},{"key":"47795_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad010","author":"D Kamori","year":"2023","unstructured":"Kamori, D. et al. Emerging integrase strand transfer inhibitor drug resistance mutations among children and adults on ART in Tanzania: findings from a national representative HIV drug resistance survey. J. Antimicrob. Chemother. https:\/\/doi.org\/10.1093\/jac\/dkad010 (2023).","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"47795_CR16","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1089\/aid.2020.0021","volume":"36","author":"S Masoud","year":"2020","unstructured":"Masoud, S. et al. Circulating HIV-1 integrase genotypes in tanzania: implication on the introduction of integrase inhibitors-based antiretroviral therapy regimen. AIDS Res. Hum. Retroviruses 36(6), 539\u2013543. https:\/\/doi.org\/10.1089\/aid.2020.0021 (2020).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"47795_CR17","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1093\/jac\/dkz256","volume":"74","author":"S Rhee","year":"2019","unstructured":"Rhee, S. et al. A systematic review of the genetic mechanisms of dolutegravir resistance. J. Antimicrob. Chemother. 74, 3135\u20133149. https:\/\/doi.org\/10.1093\/jac\/dkz256 (2019).","journal-title":"J. Antimicrob. Chemother."},{"issue":"10","key":"47795_CR18","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1093\/jac\/dkw218","volume":"71","author":"TS Boender","year":"2016","unstructured":"Boender, T. S. et al. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa. J. Antimicrob. Chemother. 71(10), 2918\u20132927. https:\/\/doi.org\/10.1093\/jac\/dkw218 (2016).","journal-title":"J. Antimicrob. Chemother."},{"key":"47795_CR19","doi-asserted-by":"publisher","unstructured":"Ngarina, M., Kilewo, C., Karlsson, K., Aboud, S., Karlsson, A., Marrone, G., Leyna, G., Ekstr\u00f6m, A. M., & Biberfeld, G. Virologic and immunologic failure, drug resistance and mortality during the first 24 months postpartum among HIV-infected women initiated on antiretroviral therapy for life in the Mitra plus Study, Dar es Salaam, Tanzania. BMC Infect. Dis. 15(1). https:\/\/doi.org\/10.1186\/s12879-015-0914-z (2015).","DOI":"10.1186\/s12879-015-0914-z"},{"key":"47795_CR20","unstructured":"HIV Drug Resistance Strategy. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/343175\/9789240030565-eng.pdf (2021)."},{"key":"47795_CR21","doi-asserted-by":"crossref","unstructured":"Schramm, B., Temfack, E., Descamps, D., Nicholas, S., Peytavin, G., Bitilinyu-Bangoh, J. E., Storto, A., L\u00ea, M. P., Abdi, B., Ousley, J., Kalua, T., Calvez, V., Jahn, A., Marcelin, A.-G., & Szumilin, E. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study. www.thelancet.com\/hiv (2022).","DOI":"10.1016\/S2352-3018(22)00136-9"},{"key":"47795_CR22","doi-asserted-by":"publisher","unstructured":"Da Silva, J., Pals, S., Chang, J., Hackett, S., Godfrey, C., & Raizes, E. Monitoring emerging human immunodeficiency virus drug resistance in Sub-Saharan Africa in the Era of Dolutegravir. J. Infect. Dis. 225(3), 364\u2013366. https:\/\/doi.org\/10.1093\/infdis\/jiab382 (2022).","DOI":"10.1093\/infdis\/jiab382"},{"issue":"1","key":"47795_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2334-14-196","volume":"14","author":"JM Juma","year":"2014","unstructured":"Juma, J. M. et al. Monitoring prevention or emergence of HIV drug resistance: Results of a population-based foundational survey of early warning indicators in mainland Tanzania. BMC Infect. Dis. 14(1), 1\u20138. https:\/\/doi.org\/10.1186\/1471-2334-14-196 (2014).","journal-title":"BMC Infect. Dis."},{"issue":"1","key":"47795_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-022-12738-4","volume":"22","author":"A Kiekens","year":"2022","unstructured":"Kiekens, A. et al. Exploring the mechanisms behind HIV drug resistance in sub-Saharan Africa: Conceptual mapping of a complex adaptive system based on multi-disciplinary expert insights. BMC Public Health 22(1), 1\u201315. https:\/\/doi.org\/10.1186\/s12889-022-12738-4 (2022).","journal-title":"BMC Public Health"},{"issue":"12","key":"47795_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pathogens10121535","volume":"10","author":"A Kiekens","year":"2021","unstructured":"Kiekens, A. et al. Factors associated with HIV drug resistance in Dar es Salaam, Tanzania: Analysis of a complex adaptive system. Pathogens 10(12), 1. https:\/\/doi.org\/10.3390\/pathogens10121535 (2021).","journal-title":"Pathogens"},{"issue":"3","key":"47795_CR26","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1093\/ije\/dyw324","volume":"46","author":"GH Leyna","year":"2017","unstructured":"Leyna, G. H. et al. Profile: The Dar Es Salaam health and demographic surveillance system (Dar es Salaam HDSS). Int. J. Epidemiol. 46(3), 801\u2013808. https:\/\/doi.org\/10.1093\/ije\/dyw324 (2017).","journal-title":"Int. J. Epidemiol."},{"issue":"11","key":"47795_CR27","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1007\/s12098-012-0763-3","volume":"79","author":"R Arya","year":"2012","unstructured":"Arya, R., Antonisamy, B. & Kumar, S. Sample size estimation in prevalence studies. Indian J. Pediatr. 79(11), 1482\u20131488. https:\/\/doi.org\/10.1007\/s12098-012-0763-3 (2012).","journal-title":"Indian J. Pediatr."},{"issue":"1","key":"47795_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5959\/eimj.v4i1.4","volume":"4","author":"WN Arifin","year":"2012","unstructured":"Arifin, W. N. Random sampling and allocation using SPSS. Educ. Med. J. 4(1), 1. https:\/\/doi.org\/10.5959\/eimj.v4i1.4 (2012).","journal-title":"Educ. Med. J."},{"key":"47795_CR29","doi-asserted-by":"publisher","unstructured":"Kiekens, A., Bwire, G. M., Decouttere, C., Jordan, M. R., Mangara, A., Mosha, I. H., Rinke De Wit, T., Sangeda, R. Z., Swalehe, O., Vandaele, N., Killewo, J., & Vandamme, A. M. HIV and SARS-CoV-2: The interplay of two wicked problems. BMJ Global Health 7(8). https:\/\/doi.org\/10.1136\/bmjgh-2022-009105 (2022).","DOI":"10.1136\/bmjgh-2022-009105"},{"key":"47795_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/DHPS.S143178","volume":"10","author":"RZ Sangeda","year":"2018","unstructured":"Sangeda, R. Z. et al. Predictors of non adherence to antiretroviral therapy at an urban HIV care and treatment center in Tanzania. Drug Healthc. Patient Saf. 10, 79\u201388. https:\/\/doi.org\/10.2147\/DHPS.S143178 (2018).","journal-title":"Drug Healthc. Patient Saf."},{"key":"47795_CR31","unstructured":"Kenya Accreditation Service. Temeke Regional Referral Hospital\u2014Specialized Laboratory. https:\/\/kenas.go.ke\/cabs\/entry\/temeke-regional-referral-hospital-specialized-laboratory\/ (2023)."},{"issue":"6","key":"47795_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/spectrum.03125-22","volume":"10","author":"J Tsch\u00e4pe","year":"2022","unstructured":"Tsch\u00e4pe, J. et al. Multisite Performance Evaluation of the cobas 5800 System and Comparison to the cobas 6800\/8800 Systems for Quantitative Measurement of HBV, HCV, and HIV-1 Viral Load. Microbiol. Spectr. 10(6), 1. https:\/\/doi.org\/10.1128\/spectrum.03125-22 (2022).","journal-title":"Microbiol. Spectr."},{"key":"47795_CR33","unstructured":"Stanford University HIV Drug Resistance Database. (n.d.). Retrieved June 9, 2023, from https:\/\/hivdb.stanford.edu\/."},{"issue":"6","key":"47795_CR34","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1128\/JCM.06689-11","volume":"50","author":"CK Woods","year":"2012","unstructured":"Woods, C. K. et al. Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool. J. Clin. Microbiol. 50(6), 1936\u20131942. https:\/\/doi.org\/10.1128\/JCM.06689-11 (2012).","journal-title":"J. Clin. Microbiol."},{"key":"47795_CR35","unstructured":"Luxembourg Institute of Health Context-based Modelling for Expeditious Typing (COMET). (n.d.). Retrieved June 9, 2023, from https:\/\/comet.lih.lu\/."},{"key":"47795_CR36","unstructured":"Rega HIV Sub-typing Tool. (n.d.). Retrieved June 9, 2023, from https:\/\/www.genomedetective.com\/app\/typingtool\/hiv."},{"key":"47795_CR37","unstructured":"WHO. (2023). The role of HIV viral suppression in improving individual health and reducing transmission. https:\/\/www.who.int\/publications\/i\/item\/9789240055179."},{"key":"47795_CR38","unstructured":"Sample Size Calculator. (n.d.). Retrieved June 9, 2023, from https:\/\/sample-size.net\/confidence-interval-proportion\/."},{"issue":"6","key":"47795_CR39","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1093\/jac\/dky062","volume":"73","author":"C Charpentier","year":"2018","unstructured":"Charpentier, C. et al. High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: Week 48 results in an observational cohort. J. Antimicrob. Chemother. 73(6), 1665\u20131671. https:\/\/doi.org\/10.1093\/jac\/dky062 (2018).","journal-title":"J. Antimicrob. Chemother."},{"issue":"37","key":"47795_CR40","doi-asserted-by":"publisher","first-page":"E21661","DOI":"10.1097\/MD.0000000000021661","volume":"99","author":"MR Jordan","year":"2020","unstructured":"Jordan, M. R. et al. High levels of HIV drug resistance among adults failing second-line antiretroviral therapy in Namibia. Medicine (United States) 99(37), E21661. https:\/\/doi.org\/10.1097\/MD.0000000000021661 (2020).","journal-title":"Medicine (United States)"},{"key":"47795_CR41","unstructured":"National Bereau of Statistics. (n.d.). Tanzania HIV Impact Survey 2016\u20132017. Retrieved March 4, 2023, from https:\/\/www.tacaids.go.tz\/documents\/research."},{"issue":"6","key":"47795_CR42","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/INF.0000000000002288","volume":"38","author":"DE Dow","year":"2019","unstructured":"Dow, D. E., Shayo, A. M., Cunningham, C. K. & Mmbaga, B. T. HIV-1 drug resistance and virologic outcomes among tanzanian youth living with HIV. Pediatr. Infect. Dis. J. 38(6), 617\u2013619. https:\/\/doi.org\/10.1097\/INF.0000000000002288 (2019).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"47795_CR43","doi-asserted-by":"publisher","unstructured":"Mziray, S. R., Kumburu, H. H., Assey, H. B., Sonda, T. B., Mahande, M. J., Msuya, S. E., & Kiwelu, I. E. Patterns of acquired HIV-1 drug resistance mutations and predictors of virological failure in Moshi, Northern Tanzania. PLoS One 15(9 September). https:\/\/doi.org\/10.1371\/journal.pone.0232649 (2020).","DOI":"10.1371\/journal.pone.0232649"},{"key":"47795_CR44","unstructured":"Centers for Disease Control and Prevention. HIV in the United States by Region: Viral Suppression. https:\/\/www.cdc.gov\/hiv\/statistics\/overview\/viral-suppression.html (2023)."},{"issue":"10","key":"47795_CR45","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1097\/QAD.0000000000002579","volume":"34","author":"CR Lesko","year":"2020","unstructured":"Lesko, C. R., Chander, G., Moore, R. D. & Lau, B. Variation in estimated viral suppression associated with the definition of viral suppression used. AIDS (London, England) 34(10), 1519\u20131526. https:\/\/doi.org\/10.1097\/QAD.0000000000002579 (2020).","journal-title":"AIDS (London, England)"},{"issue":"5","key":"47795_CR46","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1128\/jvi.73.5.4393-4403.1999","volume":"73","author":"JR Neilson","year":"1999","unstructured":"Neilson, J. R. et al. Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi. Kenya. J. Virol. 73(5), 4393\u20134403. https:\/\/doi.org\/10.1128\/jvi.73.5.4393-4403.1999 (1999).","journal-title":"Kenya. J. Virol."},{"key":"47795_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.11604\/pamj.2021.38.335.26357","volume":"38","author":"M Adhiambo","year":"2021","unstructured":"Adhiambo, M. et al. Human immunodeficiency virus (Hiv) type 1 genetic diversity in hiv positive individuals on antiretroviral therapy in a cross sectional study conducted in Teso Western Kenya. Pan Afr. Med. J. 38, 1\u201312. https:\/\/doi.org\/10.11604\/pamj.2021.38.335.26357 (2021).","journal-title":"Pan Afr. Med. J."},{"issue":"1","key":"47795_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0281528","volume":"18","author":"J Rugemalila","year":"2023","unstructured":"Rugemalila, J. et al. HIV virologic response, patterns of drug resistance mutations and correlates among adolescents and young adults: A cross-sectional study in Tanzania. PLoS One 18(1), 1. https:\/\/doi.org\/10.1371\/journal.pone.0281528 (2023).","journal-title":"PLoS One"},{"issue":"2","key":"47795_CR49","first-page":"83","volume":"14","author":"RW Lihana","year":"2012","unstructured":"Lihana, R. W., Ssemwanga, D., Abimiku, A. & Ndembi, N. Update on HIV-1 diversity in Africa: A decade in review. AIDS Rev. 14(2), 83\u2013100 (2012).","journal-title":"AIDS Rev."},{"key":"47795_CR50","doi-asserted-by":"crossref","unstructured":"Gupta-Wright, A., Corbett, E. L., Fielding, K., Grint, D. J., International, D., J van Oosterhout, M. J., Alufandika, M., Heaney, J., Byott, M., Nastouli, E., Gupta-Wright, A., Fielding, K., van Oosterhout, J. J., Alufandika, M., Grint, D. J., Chimbayo, E., Heaney, J., Byott, M., Nastouli, E., & Gupta, R. K. Virological failure, HIV-1 drug resistance, and early mortality in adults admitted to hospital in Malawi: an observational cohort study. In Articles Lancet HIV (Vol. 7). https:\/\/mafft.cbrc (2020).","DOI":"10.2139\/ssrn.3562473"},{"issue":"9","key":"47795_CR51","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1093\/cid\/ciac972","volume":"76","author":"A de Salazar","year":"2023","unstructured":"de Salazar, A. et al. Transmitted drug resistance to integrase-based first-line human immunodeficiency virus antiretroviral regimens in Mediterranean Europe. Clin. Infect. Dis. 76(9), 1628\u20131635. https:\/\/doi.org\/10.1093\/cid\/ciac972 (2023).","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"47795_CR52","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1093\/jac\/dky005","volume":"73","author":"SC Inzaule","year":"2018","unstructured":"Inzaule, S. C. et al. Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa. J. Antimicrob. Chemother. 73(5), 1167\u20131172. https:\/\/doi.org\/10.1093\/jac\/dky005 (2018).","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47795-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47795-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47795-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T15:07:33Z","timestamp":1700665653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47795-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,22]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["47795"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-47795-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,22]]},"assertion":[{"value":"18 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20493"}}